Lancet Neurology

Article	Citations
Increasing diversity in dementia research	1555
Correction to Lancet Neurol 2025; 24: 850–65	1211
The predictive value and clinical use of the neurological pupillary index – Authors' reply	1119
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	1066
Lessons and future directions for GBA1-targeting therapies	907
Multidisciplinary care for amyotrophic lateral sclerosis	647
Resolution of expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study	642
Correction to Lancet Neurol 2025; 24: 850–65	576
Correction to Lancet Neurol 2024; 23: 168–77	569
Correction to Lancet Neurol 2021; 20: 448–59	544
Traumatic brain injury research: homogenising heterogeneity	483
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	458
Correction to Lancet Neurol 2020; 19: 391–401	445
Implications of the KIWE trial for low-income and lower-middle-income countries	332
The relevance of social and commercial determinants for neurological health	318
Dementia diagnosis in the anti-amyloid era	316
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	299
RAB32 mutation in Parkinson's disease	299
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	283
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis	282
Anti-CD19 CAR T cells for refractory myasthenia gravis	278
Global burden of stroke: dynamic estimates to inform action	253
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	245
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease	237
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	237

A biological classification of Huntington's disease: the Integrated Staging System	233
Surrogate endpoints for progressive multifocal leukoencephalopathy	223
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment	213
Gene therapy for X-linked myotubular myopathy: the challenges	193
Parkinson's disease is a recognisable and useful diagnostic entity	187
Diana Cejas	187
Aspiring to restore arm and hand function after stroke	185
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	180
Albert Kwaku Akpalu	176
A chilly tale of dementia	171
A study in healing the wounds of trauma	165
A nasal CGRP receptor antagonist for acute migraine therapy	165
Trials in intracerebral haemorrhage: a path to success?	154
Delving into the human mind	151
Beyond the modular brain	150
Considering the neurological health needs of LGBTQIA people	150
A sensitive portrayal of a controversial condition	141
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	139
Epilepsy syndromes: an essential piece of the puzzle	135
Amyotrophic lateral sclerosis from genotoxins alone?	134
2025 for neuromuscular diseases: a year of multiple advances	133
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	133
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	131
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	127
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	125
Guiding the future of neurology: our peer-reviewers in 2025	124
Miratul Muqit: leading an alliance to decode Parkinson's disease	122
Global burden of headache disorders: innovations, disparities, and priorities for action	122
From stroke awareness to stroke action awareness	121
Correction to Lancet Neurol 2022; 21: 284–94	120
Correction to Lancet Neurol 2023; 22: 812–25	120
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	117
The prescription of valproate: risk of harm	117
Social connection: a fundamental need for good health	117
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	113
Functional or hysterical?	113
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	112
Multiple sclerosis in 2022: old players, new insights	112
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	112
New results for risdiplam in spinal muscular atrophy	111
Expansion of stenting indications in the USA	103
Responsible innovation in neurology	102
Jessica Ailani	102
Exploring immunomodulation with azathioprine in Parkinson's disease	100
α-synuclein seed amplification and its uses in Parkinson's disease	99
Supporting young carers across neurological disorders	96
A proposal for equity neuroscience	96
Changing multiple-sclerosis-induced thoughts and behaviours	94
Neurological infections in 2023: surveillance and prevention	92
Learning to be an adult with a disability	92

Rethinking AI trials in brain health	90
Thank you to The Lancet Neurology's peer reviewers in 2025	88
Correction to Lancet Neurol 2022; 21: 620–31	86
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	85
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	85
Correction to Lancet Neurol 2024; 23: 110–22	85
Global burden of meningitis: progress, gaps, and priorities	85
Cognitive function in people with functional seizures	84
Revisiting candesartan: new evidence for an old option in migraine prevention	83
Major advances in Parkinson's disease over the past two decades and future research directions	83
Diagnosis and pathogenesis of dystonia: clinical heterogeneity, shared mechanisms, and neurodevelopmental origins	82
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	82
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis	82
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis – Authors’ reply	81
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	80
Detection of awareness after brain injury: time for change	79
Improving thrombolysis efficiency for acute ischaemic stroke	76
ELEVATEd hope for patients after migraine treatment failure	76
Pragmatic solutions for the global burden of stroke	74
A call for optimal oral care in patients with ALS	72
Neuroprotection in acute ischaemic stroke: reasons for optimism?	72
Monitoring brainwaves while gallery visitors view artworks	72
Expanding the spectrum of type 1 IFN neuroinflammation	71
Blocking inhibitors of axon growth after spinal cord injury	69
Eugenia Martínez	69
Headache research in 2023: advancing therapy and technology	69
Sleeping matters	68
Bastiaan Bloem: power against Parkinson's disease	68
Andrea Schneider	67
Consciousness contextualised	67
Targeting auto-antibodies for CIDP: hope and questions	67
Living with dementia: seeing the world and adapting to it	67
Correction to Lancet Neurol 2024; 23: 961–62	66
Thrombolysis before endovascular treatment of tandem lesions	66
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	65
The AfrAbia+plus Parkinson's Disease Genomic Consortium	64
Epilepsy research in 2022: clinical advances	63
Questions about the brain at Edinburgh Festival Fringe	62
Caution on the use of α2δ-ligands in neuropathic pain	62
Siddharth Srivastava	61
The global challenge of hypertension	61
Correction to Lancet Neurol 2024; 23: 344–81	60
Highlights in traumatic brain injury research in 2024	60
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	59
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	59
Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	58
Diagnosis and treatment of orthostatic hypotension	57
Neurorehabilitation as a cornerstone of recovery	57
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	57
The torment of needing to know for sure	56
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	56
Angela Dos Santos	55
Correction to Lancet Neurol 2024; 23: 465–76	54
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	54
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	53
Thank you to The Lancet Neurology's peer reviewers in 2023	53
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	53
NfL is ready for translation into paediatrics	52
Charles Bell's Renaissance inspiration	51
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	51
Biomedical research must change as the climate does	50
Laquinimod, Huntington's disease, and disease modification	50
Targeting exercise, energy, or both in Friedreich's ataxia	50
Charles Sherrington's apparatus	49
Further support for rituximab in relapsing multiple sclerosis	49
Carlayne Jackson: leading the American Academy of Neurology	49
A brain design for life	49
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	48
No area of stroke research should be left behind	47
The bases of remembrance	47
The cultural history of dementia	46
Major advances in sleep neurology: 2002–22	45
Geoffrey Manley: TBI guy	45
Advances in amyotrophic lateral sclerosis research in 2022	44
Early atrial fibrillation rhythm control after stroke	44
The optimisation of migraine prevention: an urgent need	43
Neurosurgical lesioning for Tourette syndrome – Authors' reply	43
Changing the landscape of neurological education	42
Essential medicines for neurological disorders: updates, rejections, and the road ahead	41
Digital mobility measures to predict Parkinson's disease	41

The complex pathway between amyloid β and cognition: implications for therapy	40
Sleep research in 2023: beyond the bare necessities	39
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	39
Improving epilepsy diagnosis across the lifespan: approaches and innovations	39
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	39
Therapies for myasthenia gravis: FcRn inhibition and beyond	38
For a dementia diagnosis, clinical acumen must precede biomarkers	37
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	37
Over a decade of MR-guided focused ultrasound	37
Nanna Brix Finnerup: integrity and openness to alternatives	37
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	37
Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings	37
Helping to bring the crisis home	36
Blue as an orange	36
Sleep matters in anti-LGI1 encephalitis	36
Maria Trojano: advocate for real-world multiple sclerosis studies	35
Video games for people with neurological disorders	35
Nitrous oxide and its neurological harms	35
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case series	35
Revisiting levodopa for advanced Parkinson's disease	34
The prescription of valproate: risk of harm	34
Correction to Lancet Neurol 2023; 22: 209–17	33
Correction to Lancet Neurol 2021; 20: 615–26	33
Correction to Lancet Neurol 2025; 24: 413–28	33
Global burden of meningitis and implications for strategy	32
Time to get serious about the Global Action Plan on dementia	32
Lifestyle interventions for Parkinson's disease	32
Abandon the NAC in α-synuclein	32
RAB32 mutation in Parkinson's disease	32
Correction to Lancet Neurol 2025; 24: 880–92	32
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD	31
Correction to Lancet Neurol 2025; 24: 969–75	31
Neuroscience research in 2024: advances in blood biomarkers and brain omics	31
Globally advancing neurological education in headache	31
Brain amyloid on the way to dementia prevention	31
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	30
Correction to Lancet Neurol 2024; 23: 344–81	30
Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications	30
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	29
Advances in diagnosis, classification, and management of pain in Parkinson's disease	29
Addressing neurological burden in the Americas	29
Blood pressure reduction and reperfusion therapy	29
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	29
A neurotransmitter with a fascinating story	29
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	29
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	29
William Harvey, neurologist?	28
A disease-specific therapy in facioscapulohumeral muscular dystrophy	28
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	27
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	27
Neurology cannot be embedded in non-communicable disease agendas	26
Cerebral amyloid angiopathy criteria: the next generation	26
Krithi Irmady	26
Innovation in the prevention of neurological diseases	26
The hidden unity of the mind	26
Vittorio Marchi's staining	24
With thanks to our peer reviewers in 2022	24
Fetal exposure to antiseizure medications: reassurance and concerns	24
Treatment of asymptomatic carotid stenosis in SPACE-2	24
Treatment of acute subdural haematoma – Authors' reply	24
Transforming amyotrophic lateral sclerosis into a liveable disease	24
Neuropsychiatry on screen	23
Differential diagnosis of suspected multiple sclerosis: global health considerations	23
CGRP blockade and cluster headache: another step forward	23
Correction to Lancet Neurol 2019; 18: 748–59	23
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	22
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	22
Time to end the stigma of epilepsy	22
Amyotrophic lateral sclerosis: a lesson in translation	22
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	22
Carotid revascularisation for carotid stenosis	22
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	21
Carpal tunnel syndrome: updated evidence and new questions	21
The Stimming Pool: an autistic production	21
Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	21
Changing views of disability	20
Elucidating a new path of CSF transport in the CNS	20
Chronic effects of inflammation on tauopathies	20
Mar Tintoré, Mar Mediterráneo	19
Turin as a neuroscience cradle	19
Antibiotic neuromuscular junction myasthenic mimetics	19
Alzheimer's disease: a history revisited	19
Karen Duff: blazing a path in dementia research	19
Rigmor Højland Jensen: the headache warrior	19
A genetic basis for the severity of multiple sclerosis	18
Limping into oblivion	18
Correction to Lancet Neurol 2025; 24: 486–87	18
Neuropsychiatric research in 2023: mechanisms of stress and therapies	18
Nosferatu and the cinematic unglory of hysteria	17
Correction to Lancet Neurol 2023; 22: 1089–91	17
Takeshi Iwatsubo: a pioneer in Alzheimer's disease research	17
Are CAR T cells the answer to myasthenia gravis therapy?	16
Criteria for a biological definition of neuronal α-synuclein disease—a major conceptual step forward	16
Everything is connected: sparks will fly in coproduction spaces	16
Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease	16